KRAS G12D drugs for Pancreatic Ductal Adenocarcinoma
4 tracked KRAS G12D drugs in the Pancreatic Ductal Adenocarcinoma race. The class explanation lives on the KRAS G12D page; the full indication pipeline across every mechanism is on the Pancreatic Ductal Adenocarcinoma page.
2 Phase 31 Phase 21 preclinical / unstaged